🏅 FDA Orphan Designation
LUMOXITI
moxetumomab pasudotox-tdfk
Manufacturer: AstraZeneca Pharmaceuticals LP
Indicated for:
FDA-Approved Indications (1)
Classic hairy cell leukemiaOrphan Designation
LUMOXITI is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nu…
Indications & Usage
LUMOXITI is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA).
💙 Support Programs
View all →LUMOXITI
AstraZeneca Pharmaceuticals LP
Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.
Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.